Abstract
Maturity Onset Diabetes of the Young (MODY) is an autosomal dominant form of monogenic diabetes, reported to be caused by variants in 16 genes. Concern has been raised about whether variants in BLK (MODY11), KLF11 (MODY7) and PAX4 (MODY9) cause MODY. We examined variant-level genetic evidence (co-segregation with diabetes and frequency in population) for published putative pathogenic variants in these genes and used burden testing to test gene-level evidence in a MODY cohort (n=1227) compared to population control (UK Biobank, n=185,898). For comparison we analysed well-established causes of MODY, HNF1A and HNF4A. The published variants in BLK, KLF11 and PAX4 showed poor co-segregation with diabetes (combined LOD scores ≤1.2), compared to HNF1A and HNF4A (LOD scores >9), and are all too common to cause MODY (minor allele frequency >4.95×10−5). Ultra-rare missense and protein-truncating variants (PTVs) were not enriched in a MODY cohort compared to the UK Biobank (PTVs P>0.05, missense P>0.1 for all three genes) while HNF1A and HNF4A were enriched (P<10−6). Sensitivity analyses using different population cohorts supported our results. Variant and gene-level genetic evidence does not support BLK, KLF11 or PAX4 as causes of MODY. They should not be included in MODY diagnostic genetic testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The current work was funded by Diabetes UK (19/0005994) and the MRC (grant no MR/T00200X/1). The authors would like to acknowledge use of the University of Exeter High-Performance Computing (HPC) facility in carrying out this work. T.W.L is supported by a lectureship funded by Research Englands Expanding Excellence in England (E3) fund. K.A.P has a Career Development fellowship funded by the Wellcome Trust (219606/Z/19/Z). A.T.H. was a recipient of a Wellcome Trust Senior Investigator award (grant WT098395/Z/12/Z) and is employed as a core member of staff within the NIHR funded Exeter Clinical Research Facility and is an NIHR senior investigator.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the North Wales ethics committee (17/WA/03)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The GnomAD datasets are publicly available (https://gnomad.broadinstitute.org/). Data from the the UK Biobank is available to researchers by application to the access committee (https://www.ukbiobank.ac.uk/). For the MODY cohort the genotype data could be used to identify individuals and so cannot be made openly available. Access to data is open only through collaboration. Requests for collaboration will be considered following an application to the Genetic Beta Cell Research Bank (https://www.diabetesgenes.org/current-research/genetic-beta-cell-research-bank/). Contact by email should be directed to the Lead Nurse, Dr Bridget Knight (b.a.knight{at}exeter.ac.uk).
